Focused On-demand Library for Testis-specific chromodomain protein Y 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y6F7

UPID:

CDY2_HUMAN

Alternative names:

Alternative UPACC:

Q9Y6F7; A8K868

Background:

Testis-specific chromodomain protein Y 2, identified by the accession number Q9Y6F7, is suggested to possess histone acetyltransferase activity. This activity is crucial for the regulation of gene expression through the modification of chromatin structure, allowing for the transcription machinery to access DNA. As a testis-specific protein, it plays a unique role in spermatogenesis and may influence chromatin remodeling processes specific to male gamete formation.

Therapeutic significance:

Understanding the role of Testis-specific chromodomain protein Y 2 could open doors to potential therapeutic strategies. Its involvement in chromatin remodeling and gene expression regulation in the testis suggests its potential impact on male fertility. Targeting this protein could lead to innovative treatments for male infertility, offering hope to many affected individuals.